Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KRAS inhibitor BI 3706674

An orally bioavailable small molecule inhibitor that targets the oncogenic KRAS wild-type (WT) and various KRAS mutant forms, such as KRAS G12C, with potential antineoplastic activity. Upon oral administration, KRAS inhibitor BI 3706674 selectively binds to KRAS, thereby inhibiting KRAS-dependent signaling and inhibits growth and survival of KRAS-overexpressing and mutated tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	BI 3706674 BI-3706674 BI3706674

KRAS inhibitor BI 3706674

Search NCI's Drug Dictionary